Stock Market News For Nov 12, 2018
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put United Therapeutics Corporation UTHR stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, United Therapeutics has a trailing twelve months PE ratio of 6.9, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.2. If we focus on the stock’s long-term PE trend, the current level puts United Therapeutics’ current PE ratio somewhat below its midpoint (which is 14.3) over the past five years.
Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 90.9. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that United Therapeutics has a forward PE ratio (price relative to this year’s earnings) of 8.9, so it is fair to expect an increase in the company’s share price in the near future.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, United Therapeutics has a P/S ratio of about 3.1. This is slightly lower than the S&P 500 average, which comes in at 3.5 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.
If anything, this suggests some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, United Therapeutics currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes UTHR a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio (another great indicator of value) comes in at 10.2, which is slightly better than the industry average of 11.8. Clearly, UTHR is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though United Therapeutics might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of C and a Momentum score of A. This gives UTHR a VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen five estimates go higher in the past sixty days, compared to none lower, while the full year estimate has seen five upward and one downward revision in the same time period.
This has had a favorable impact on the consensus estimate, as the current quarter consensus estimate has increased nearly 23% in the past two months, while the full year estimate has risen about 8.7%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
United Therapeutics Corporation Price and Consensus
United Therapeutics Corporation Price and Consensus | United Therapeutics Corporation Quote
Even though United Therapeutics has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). That is why we are looking for in-line performance from the company in the near term.
United Therapeutics is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a strong industry rank (top 43% out of more than 250 industries) further supports the growth potential of the stock. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:
Despite positive estimate revision activity, investors should wait for industry trends to turn around first. When it does, this stock could be a compelling value pick.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Therapeutics Corporation (UTHR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research